Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | BET Inhibitor pelabresib (CPI-0610) and ruxolitinib for myelofibrosis

Srdan Verstovsek • 15 Jun 2019
EHA 2019
Myelofibrosis Pelabresib Ruxolitinib

Here, Srdan Verstovsek, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, presents updates on the use of the BET Inhibitor pelabresib (CPI-0610) in combination with ruxolitinib for myelofibrosis. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Srdan Verstovsek

An update on the use of navtemadlin in myelofibrosis
1:52
An update on the use of navtemadlin in myelofibrosis
Srdan Verstovsek • 7 Dec 2022
Insights into the Phase IIa Mylox-1 trial: assessing efficacy of GB2064 in myelofibrosis
2:19
Insights into the Phase IIa Mylox-1 trial: assessing efficacy of GB2064 in myelofibrosis
Srdan Verstovsek • 7 Dec 2022
FIGHT-203 trial: pemigatinib in patients with MLNs with FGFR1 rearrangement
2:19
FIGHT-203 trial: pemigatinib in patients with MLNs with FGFR1 rearrangement
Srdan Verstovsek • 7 Dec 2022
Rationale for VERIFY: rusfertide added to ongoing therapy in patients with polycythemia vera
1:56
Rationale for VERIFY: rusfertide added to ongoing therapy in patients with polycythemia vera
Srdan Verstovsek • 7 Dec 2022

Related Videos

When to switch JAK inhibitor therapy in myelofibrosis
1:08
When to switch JAK inhibitor therapy in myelofibrosis
John Mascarenhas • 1 Oct 2026
Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
1:36
Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
John Mascarenhas • 1 Oct 2026
Emerging therapeutic strategies and future directions in MPNs
3:00
Emerging therapeutic strategies and future directions in MPNs
Lucia Masarova • 4 Oct 2026
MPN Progression Registry: insights into the work of the MPN Research Foundation
19:15
MPN Progression Registry: insights into the work of the MPN Research Foundation
David Shoultz et al. • 2 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals